Medigen Vaccine Biologics Corporation reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 326.63 million compared to TWD 3.14 million a year ago. Net loss was TWD 140.37 million compared to TWD 156.9 million a year ago. Basic loss per share from continuing operations was TWD 0.4451 compared to TWD 0.4991 a year ago. Basic loss per share was TWD 0.4451 compared to TWD 0.4991 a year ago.